Spore.Bio secures $23M to advance AI microbiology testing

Spore.Bio, a Paris-based deeptech startup specializing in microbiology testing, has raised $23 million in a Series A funding round, enhancing its total funding to $31.3 million. The company aims to revolutionize quality control in the food, pharmaceutical, and cosmetics industries by offering rapid on-site bacteria detection using machine learning technology. Traditional microbiological tests can take from five days to two weeks, posing significant risks of contamination and costly recalls, averaging around $10 million per incident. Spore.Bio's innovative approach utilizes spectral signature analysis to provide near-instant results, allowing manufacturers to proactively manage quality control and prevent contamination issues. The funding round was led by Singular, with participation from several venture firms, reflecting strong market demand and interest in the startup's technology. Founded in 2023 by a team with extensive industry experience, Spore.Bio is now supporting its first customers and has opened a waitlist for future deployments.